James Del Rosso, DO, lit up the room with a rapid-fire tour of dermatology’s hottest updates, spanning acne, inflammatory skin conditions, and skin cancer. He kicked things off with tirbanibulin, now approved for large-field treatment of actinic keratosis (up to 100 cm²), then explored the latest updates on atopic dermatitis, highlighting long-term data on dupilumab (including re-initiation after discontinuation), and shared exciting efficacy results from IL-13 inhibitors tralokinumab and lebrikizumab, as well as JAK inhibitors upadacitinib and abrocitinib. Next up: alopecia areata—where Dr Del Rosso showcased groundbreaking data on deuruxolitinib, baricitinib, and ritlecitinib, while urging providers to look beyond the SALT score and focus on patient-centered outcomes. He maintained the momentum with an update on hidradenitis suppurativa (HS), highlighting emerging insights into risk factors and disease mechanisms, as well as recent advances in treatment. These include FDA-approved monoclonal antibody therapies such as the IL-17 inhibitors secukinumab and bimekizumab, along with the investigational JAK1 inhibitor povorcitinib, which is currently in Phase 3 trials for moderate to severe HS.